The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).
 
Angel Arnaout
No Relationships to Disclose
 
Melanie Spears
No Relationships to Disclose
 
Arif Ali Awan
Honoraria - Apotex; AstraZeneca Canada; Roche Canada
Consulting or Advisory Role - AstraZeneca Canada; Exact Sciences; Exact Sciences; Foundation Medicine; Lilly; Lilly; Novartis Canada Pharmaceuticals Inc; Novartis Canada Pharmaceuticals Inc; Pfizer; Pfizer; Roche Canada
Research Funding - Astellas Pharma (Inst); Exactis Innovation (Inst); Intensity Therapeutics (Inst); Roche (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Roche/Genentech; Roche/Genentech
 
Susan Robertson
No Relationships to Disclose
 
Kianoosh Keyhanian
No Relationships to Disclose
 
Gregory Russell Pond
Employment - Roche Canada (I)
Stock and Other Ownership Interests - Roche Canada (I)
Honoraria - AstraZeneca; AstraZeneca
Consulting or Advisory Role - Merck; Profound Medical; Takeda
 
John Bartlett
Leadership - MedcomXchange
Honoraria - bioTheranostics; MedcomXchange; NanoString Technologies; Oncology Education
Consulting or Advisory Role - BioNTech; bioTheranostics; Herbert Smith Freehills Paris; Herbert Smith Freehills Paris; Insight Genetics; OncoCyte; oncoXchange; Pfizer; RNA Diagnostics
Research Funding - Agendia; bioTheranostics; Genoptix; NanoString Technologies; Stratifyer GmbH; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Invention Disclosure Name: A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer Date: 21/08/2019 (Inst); John Bartlett currently has 1 allowed patent: Jan 2021: Histone gene module predicts anthracycline benefit, PCT/CA2016/000247 (Inst); John Bartlett currently has 5 pending patents: 1. Jan 2017: Methods and Devices for Predicting Anthracycline Treatment Efficacy, US utility – 15/325,472; EPO – 15822898.1; Canada – not yet assigned; 2. Jan 2017: Systems, Devices and Methods for Constructi (Inst)
Travel, Accommodations, Expenses - bioTheranostics; Breast Cancer Society of Canada; NanoString Technologies
 
Vanessa Lopez-Ozuna
No Relationships to Disclose
 
Syed Mahmood
Employment - Intensity Therapeutics
Leadership - Intensity Therapeutics
Research Funding - Intensity Therapeutics
 
Lewis H. Bender
Employment - Intensity Therapeutics
Leadership - Intensity Therapeutics
Stock and Other Ownership Interests - Intensity Therapeutics
Research Funding - Intensity Therapeutics
Patents, Royalties, Other Intellectual Property - Intensity Therapeutics
 
Ian B. Walters
Employment - Intensity Therapeutics
Leadership - Intensity Therapeutics
Stock and Other Ownership Interests - Intensity Therapeutics
Research Funding - Intensity Therapeutics